BREXPIPRAZOLE | BREXPIPRAZOLE | ATC N05AX16
NERVOUS SYSTEM ANTIPSYCHOTIC TREATMENT OF MAJOR DEPRESSIVE DISORDER OR SCHIZOPHRENIA COMBINATION OF PARTIAL AGONIST ACTIVITY AT SEROTONIN 5-HT1A (KD = 0.12 NANOMOLAR) AND DOPAMINE D2 (KD = 0.30 NANOMOLAR) AND ANTAGONIST ACTIVITY AT SEROTONIN 5-HT2A RECEPTORS (KD= 0.47 NANOMOLAR) | ORAL | Tmax 4 HOUR F 95 PERCENT VD 101.4 LITER (65 KILOGRAM) PPB 99 PERCENT Cl 1.28 LITER / HOUR (65 KILOGRAM) HT 91 HOUR | 5-HT1A RECEPTORS DOPAMINE D2 RECEPTOR 5-HT2A RECEPTOR | SEROTONIN 1A (5-HT1A) RECEPTOR PARTIAL AGONIST CHEMBL214 SEROTONIN 1A (5-HT1A) RECEPTOR P08908 5-HYDROXYTRYPTAMINE RECEPTOR 1A HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR SEROTONIN RECEPTOR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |